<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548869</url>
  </required_header>
  <id_info>
    <org_study_id>CDX0159-03</org_study_id>
    <secondary_id>2020-002792-35</secondary_id>
    <nct_id>NCT04548869</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria</brief_title>
  <official_title>An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria,&#xD;
      Symptomatic Dermographism, or Cholinergic Urticaria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label Phase 1 study evaluating the safety, pharmacokinetics, and&#xD;
      pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria,&#xD;
      Symptomatic Dermographism, or Cholinergic Urticaria who remain symptomatic despite treatment&#xD;
      with antihistamines. Twenty patients with Cold Contact Urticaria, ten patients with&#xD;
      Symptomatic Dermographism, and ten patients with Cholinergic Urticaria will be enrolled in&#xD;
      four separate cohorts for a total of 40 patients.&#xD;
&#xD;
      Prospective patients will be screened with tests in clinic as well as daily at home diaries&#xD;
      for 2 weeks prior to enrollment. CDX-0159 will be administered intravenously on Day 1.&#xD;
      Post-treatment, patients will be followed for 12 weeks with an optional longer term follow up&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by the incidence and severity of adverse events</measure>
    <time_frame>From Day 1 through week 12</time_frame>
    <description>Safety of a single dose of CDX-0159 as determined by adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For patients with Cold Contact Urticaria, Change in Critical Temperature Thresholds (CTT)</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>The change from baseline in critical temperature thresholds over time as determined by provocation testing using the TempTest®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients with Symptomatic Dermographism, change in provocation thresholds</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>The change from baseline in provocation thresholds over time as determined by provocation testing using the FricTest®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients with Cholinergic Urticaria, changes in baseline Urticaria Activity Score Provocation (UASprovo)</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>Changes from baseline and percentage of responders as measured by UASprovo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Urticaria Control Test (UCT)</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>Changes from baseline and percentage of responders for the UCT and modified UCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Biomarkers</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in Stem Cell Factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Biomarkers</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in tryptase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>CDX-0159 concentrations will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Evaluation</measure>
    <time_frame>From Day 1 to Day 85</time_frame>
    <description>Patients will be monitored for the development of anti-drug antibodies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cold Urticaria</condition>
  <condition>Cold Contact Urticaria</condition>
  <condition>Symptomatic Dermographism</condition>
  <condition>Symptomatic Dermatographism</condition>
  <condition>Cholinergic Urticaria</condition>
  <arm_group>
    <arm_group_label>CDX-0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-0159</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>CDX-0159</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic&#xD;
             Urticaria which does not respond to antihistamines&#xD;
&#xD;
               -  Diagnosis for ≥ 3 months; symptoms of both hive (wheal) and itch/burning/painful&#xD;
                  sensation despite concurrent use of anti-histamines&#xD;
&#xD;
               -  During screening, in clinic, for Cold Contact Urticaria, patients must have a&#xD;
                  positive cold stimulation test, for Symptomatic Dermographism, patients must have&#xD;
                  a positive FricTest®, and for Cholinergic Urticaria, patients must have a&#xD;
                  positive pulse-controlled ergometry (PCE) provocation test&#xD;
&#xD;
               -  On stable dose of antihistamines&#xD;
&#xD;
          2. Other than a diagnosis of Cold Contact Urticaria, Symptomatic Dermographism, or&#xD;
             Cholinergic Urticaria, no other conditions which would introduce additional risk&#xD;
             factors or would interfere with the study procedures, as determined by the&#xD;
             investigator, based on a medical evaluation&#xD;
&#xD;
          3. Female and male patients must use highly effective contraception from the time of the&#xD;
             screening visit and for at least 150 days after receipt of study treatment&#xD;
&#xD;
          4. Willing and able to comply with all study requirements and procedures including&#xD;
             completion of a daily medication diary and questionnaires&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. A clearly defined diagnosis of hives or angioedema other than chronic urticaria.&#xD;
&#xD;
          2. Receipt of prior biologic therapy (e.g.: omalizumab, dupilumab, ligelizumab) within&#xD;
             past 3 months&#xD;
&#xD;
          3. Treatment with immunosuppressives (e.g. systemic corticosteroids, cyclosporine,&#xD;
             methotrexate, dapsone, cyclophosphamide, tacrolimus and mycophenolate mofetil,&#xD;
             hydroxychloroquine or others) within 4 weeks or 5 half lives&#xD;
&#xD;
          4. Active COVID-19 infection&#xD;
&#xD;
          5. HIV, hepatitis B or hepatitis C infection&#xD;
&#xD;
        There are additional criteria that your study doctor will review with you to confirm you&#xD;
        are eligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <phone>844-723-9363</phone>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Maurer, Prof.</last_name>
      <email>marcus.maurer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Maurer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

